Tcld55...yes you have been here a long while too...remember the RB message board : )
Anyways last paragraph which this is taken from the 10-K ENDING 12-31-11 PAGE 32
In June 2011, the Canadian Intellectual Property Office issued a notice of allowance of the Company’s application covering computer-aided image analysis using SVMs. Counterpart patents have already issued in the U.S. (two patents), Australia, Europe and Japan.
In July 2011, the U.S. Patent and Trademark Office issued a notice of allowance of the application that the Company had filed the preceding November with claims copied from the Intel patent that claimed RFE-SVM. This application was filed to provoke an interference proceeding against the Intel patent in the U.S. Patent and Trademark Office. The allowance was later withdrawn in conjunction with an evaluation of the prospective interference. The Company is now awaiting action by the Interference Division to initiate the interference proceedings.
In August 2011, the U.S. Patent and Trademark Office issued a new patent to the Company covering a group of genes which exhibit reduced expression relative to normal in the presence of prostate cancer. The claimed biomarkers may be of particular value in tests using DNA methylation methods. Prior to issuance of the new patent a continuation application was filed to seek coverage of additional biomarker combinations that were disclosed in the application. Also in August, the Canadian Intellectual Property Office issued a patent covering to the Company covering a method of enhancing knowledge discovered from multiple data sets using multiple support vector machines.
In September 2011, the Canadian Intellectual Property Office issued a notice of allowance of the Company’s second Canadian application covering the SVM-RFE method. Also in September, the U.S. Patent and Trademark Office issued a notice of allowance of the continuation application that had been filed in December 2010 with further expanded claims to the SVM-RFE method. The claims of this application correspond to those granted in the European application that had been granted in January 2011. After issuance of the allowed applications, the Company will hold nine U.S and foreign patents covering SVM-RFE. This new U.S. patent issued in January 2012.
With the issuance of these patents, the Company now holds the exclusive rights to 59 issued and 31 pending U.S. and foreign patents covering uses of SVM and FGM technology for discovery of knowledge from large data sets.
The Company launched its new academic/research institution licensing program in the third quarter of 2011 by sending letters to a test group of universities and research institutions that have reported the use of SVMs in academic journals and conference proceedings. The letters received mixed responses, with some of the contacted institutions being receptive to entering into license negotiations. The Company’s proposed terms include a paid-up license against past and future infringement of the Company’s patented technology for a nominal one-time license administrative fee, plus a reach-through provision with royalties payable on any revenue generated when the results of the SVM usage are licensed for commercialization. To date, more than 50 U.S. institutions have been identified as using SVM-RFE and SVM through review of academic publications, with many of the reported uses relating to biomarker discovery and medical diagnostics.
___________________
Now ask since I posted a prior message about management in their own words stating no money, and and no doubt employees in 2011 yet now we have at least 5 directors which I am including the CEO what have they done referencing the above paragraph?...mainly the red eye part!
So where is the beef? you mean NOT even 1 University or other insitution?
